Directeur de recherche (DR1) à L’INSERM
Frank Lezoualc'h est expert de l'identification de nouvelles cibles thérapeutiques contre l'insuffi-sance cardiaque. Il a contribué à la caractérisation fonctionnelle des protéines AMP cycliques Epac et Carabine dans les maladies cardiaques. Les travaux de son groupe ont permis d’identifier des inhibiteurs pharmacologiques d'Epac1 et leur utilisation potentielle comme molécules thérapeutiques dans plusieurs maladies.
INSERM research director (DR1) INSERM
Frank Lezoualc’h is expert in the identification of novel therapeutic target for heart failure. He has provided significant contributions elucidating the role and signaling of the cyclic AMP Epac proteins and Carabin in cardiac disease. He was pioneer in the characterization of Epac1 pharmacological inhibitors and their potential use as therapeutic molecules in several diseases.
Career path Frank Lezoualc’h obtained his PhD in Molecular Endocrinology from the University Pierre & Marie Curie, Paris in 1995. After a postdoc at the Max-Planck Institute in Munich, he developed his own group in molecular cardiology at Inserm, University of Paris-Saclay in 2000. He joined I2MC of Toulouse in 2010 as research director at Inserm and team leader.
Main domains of expertise Signaling, cardiac remodeling, cardiovascular diseases, therapeutic innovation.